OncLive TV

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.

Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Emad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.

Douglas R. Lowy, MD, acting director, National Cancer Institute, chief, Laboratory of Cellular Oncology, senior Investigator, Head, Signaling and Oncogenesis Section, discusses vaccines that may show efficacy in certain tumor types.

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Jedd Wolchok, MD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center discusses combining targeted and immunotherapies.

Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.

Anne Marie McCarthy, MD, research fellow, Massachusetts General Hospital, discusses using computer algorithms to measure breast density.

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses how bevacizumab could be effective in tumor types beyond ovarian cancer.

Tara Sanft, MD, assistant professor of medicine, director, Survivorship Clinic, Smilow Cancer Hospital at Yale-New Haven, discusses survivorship care plans and how they can differ among patients.

Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.

Dan Beachler, MD, fellow at the National Cancer Institute, discusses the efficacy of the HPV vaccine on individuals who have been previously exposed to the virus compared to those who have not.

Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer risk.

Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).